Relationship between the peripheral neuropathy due to anticancer drugs and vibration sense or nerve conduction velocity in cancer patients

• Project/Area Number: 15K08675
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pain science
• Research Institution: Oita University
• Principal Investigator: Shirao Kuniaki 大分大学, 医学部, 教授 (10467996)
• Co-Investigator(Kenkyū-buntansha): 佐藤 雄己 大分大学, 医学部, 副薬剤部長 (00570087) ; 久松 靖史 大分大学, 医学部, 病院特任助教 (00609670) ; 緒方 正男 大分大学, 医学部, 講師 (10332892) ; 平島 詳典 大分大学, 医学部, 助教 (60418837) ; 幸野 和洋 大分大学, 医学部, 助教 (80420644) ; 大津 智 大分大学, 医学部, 講師 (80437920) ; 西川 和男 大分大学, 医学部, 病院特任助教 (70636399) ; 小森 梓 大分大学, 医学部, 病院特任助教 (60799295)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000); Fiscal Year 2017: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000); Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 抗がん剤 / 副作用 / しびれ / 音叉検査値 / 神経伝導速度 / 末梢神経障害 / オキサリプラチン / パクリタキセル / 抹消神経障害 / 組織変異 / 遺伝子多型 / 軸索密度

Outline of Final Research Achievements

From the viewpoint of reducing the side effects or improving treatment outcomes, it is important to clarify the mechanism of development of peripheral neuropathy (numbness) by various anti-cancer drugs, to clarify the predictive factors for expression and to find a coping strategy. Up to now, we have examined the frequency of occurrence of neurotoxicity of anticancer drugs, the extent of neurotoxicitiy, and the amount of drug exposure to neurotoxicity expression in cancer patients. On the basis of these results, we are conducting a prospective study to clarify the relation between the peripheral neuropathy in cancer patients using anticancer drugs and vibration sense or nerve conduction velocity.

Research Products

• [Journal Article] Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). (2015)
  • Author(s): Nishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K, Mizusawa J, Nakamura K, Shirao K, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group
  • Journal Title: Gastric Cancer. Volume: なし Pages: 1-9
  • Peer Reviewed
• [Journal Article] A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. (2015)
  • Author(s): Yamazaki K1, Kuwano H, Ojima H, Otsuji T, Kato T, Shimada K, Hyodo I, Nishina T, Shirao K, Esaki T, Ohishi T, Denda T, Takeuchi M, Boku N
  • Journal Title: Cancer Chemother Pharmacol. Volume: なし Pages: 569-577
  • Peer Reviewed